Handelsbanken Fonder’s Apogee Therapeutics APGE Stock Holding History

Handelsbanken Fonder’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.5M	Buy	86,300 +65,200	+309%	+$5.87M	0.03%	366
2026 Q1	$1.78M	Buy	21,100 +8,400	+66%	+$610K	0.01%	789
2025 Q4	$959K	Buy	12,700 +4,200	+49%	+$265K	﹤0.01%	1046
2025 Q3	$338K	Hold	8,500	–	–	﹤0.01%	1399
2025 Q2	$369K	Buy	8,500 +1,000	+13%	+$38K	﹤0.01%	1365
2025 Q1	$280K	Hold	7,500	–	–	﹤0.01%	1423
2024 Q4	$340K	Sell	7,500 -1,300	-15%	-$66.3K	﹤0.01%	1422
2024 Q3	$517K	Buy	8,800 +1,800	+26%	+$86.2K	﹤0.01%	1229
2024 Q2	$275K	Buy	+7,000	New	+$340K	﹤0.01%	1416

Other funds holding APGE

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

AFC

Ares Financial Consulting Calabasas, California $139M AUM

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Handelsbanken Fonder's APGE Position: Q2 2026 in Review

Handelsbanken Fonder increased its Apogee Therapeutics (APGE) stake by 309% in Q2 2026, buying an estimated $5.87M and bringing the position to 86,300 shares worth $11.5M. The position accounts for 0.03% of the portfolio, ranked #366.

Handelsbanken Fonder first reported a position in APGE in Q2 2024 and has held it in 9 quarters since. 8 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Handelsbanken Fonder held 86,300 shares of Apogee Therapeutics worth $11.5M as of Q2 2026.
Handelsbanken Fonder bought 65,200 Apogee Therapeutics shares in Q2 2026, an estimated $5.87M.
Apogee Therapeutics made up 0.03% of Handelsbanken Fonder's portfolio in Q2 2026, its #366 holding.
Handelsbanken Fonder first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 9 quarters since.
8 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.